The Chairman's Report gives us guidance on the progress of the Janssen collaboration;
"Successful delivery on this project should trigger a significant licence fee payment in early 2014," page 3.
So what is early 2014? The Director's Report provides a tighter timeline;
"In February 2014 Phylogica hopes to achieve a major technical milestone for the Janssen collaboration that can potentially trigger a significant licence payment," page 18.
So it would appear that early 2014 is in fact February 2014. A licencing deal with Janssen would be transformational. Not only would it "create opportunities to further expand the relationship with Janssen" but it would also provide compelling validation for the technology. There is much to play for despite the lean year of deal flow.
- Forums
- ASX - By Stock
- janssen
The Chairman's Report gives us guidance on the progress of the...
-
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.0¢ |
Change
0.005(2.70%) |
Mkt cap ! $886.5M |
Open | High | Low | Value | Volume |
18.5¢ | 19.0¢ | 17.5¢ | $508.8K | 2.763M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 118941 | 18.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.0¢ | 183634 | 2 |
Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online